Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AKN-028 是酪氨酸激酶 FLT3的抑制剂,可剂量依赖性的诱导 FLT3的自磷酸化。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 342 | 现货 | ||
5 mg | ¥ 798 | 现货 | ||
10 mg | ¥ 1,360 | 现货 | ||
25 mg | ¥ 2,800 | 现货 | ||
50 mg | ¥ 4,160 | 现货 | ||
100 mg | ¥ 5,930 | 现货 | ||
500 mg | ¥ 11,900 | 现货 |
产品描述 | AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation. |
靶点活性 | FLT3:6 nM (IC50), CLK1:140 nM (IC50), FGFR2:1200 nM (IC50), RPS6KA:220 nM (IC50), VEGFR2:520 nM (IC50) |
体外活性 | AKN-028 triggers apoptosis in MV4-11 by activation of caspase 3 [1] . AKN-028 (10 μM) is cytotoxic to AML cell lines and induces apoptosis in the AML cell line MV4-11 [1] . Cell Cytotoxicity Assay [1] Cell Line: AML cell line MV4-11. Concentration: 10 μM. Incubation Time: 24 h. Result: Was cytotoxic to primary AML cells, irrespective of FLT3 mutation status and quantitative FLT3 expression. |
体内活性 | AKN-028 (15?mg/kg, Subcutaneously injection twice daily) exhibits anti-tumor activities for acute myeloid leukemia (AML) models [1] . Animal Model: Mice based AML and MV4-11 cells [1] . Dosage: 15?mg/kg. Administration: Subcutaneously injection twice daily. Result: Inhibited net growth of one of the primary AML samples (UPN26) in vivo and furthermore reduced the tumor mass of MV4-11 cell line. |
分子量 | 302.33 |
分子式 | C17H14N6 |
CAS No. | 1175017-90-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 1.43 mg/mL (4.73 mM), Sonification is recommended
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.3076 mL | 16.5382 mL | 33.0764 mL | 82.6911 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AKN-028 1175017-90-9 Angiogenesis Tyrosine Kinase/Adaptors FLT inhibit Cluster of differentiation antigen 135 Inhibitor Fms like tyrosine kinase 3 Caspase acute myeloid leukemia CD135 Apoptosis FLT3 AKN028 AML cell lines cytotoxic FLT3 autophosphorylation AKN 028 inhibitor